Bakhru
Hassaram Bakhru, Loudonville, NY US
Patent application number | Description | Published |
---|---|---|
20120097209 | FABRICATION OF SURFACE TEXTURES BY ION IMPLANTATION FOR ANTIREFLECTION OF SILICON CRYSTALS - The invention relates to a new method of texturing silicon surfaces suited for antireflection based on ion implantation of hydrogen and heavy ions or heavy elements combined with thermal annealing or thermal annealing and oxidation. The addition of the heavy ions or heavy elements allows for a more effective anti-reflective surface than is found when only hydrogen implantation is utilized. The methods used are also time- and cost-effective, as they can utilize already existing semiconductor ion implantation fabrication equipment and reduce the number of necessary steps. The antireflective surfaces are useful for silicon-based solar cells. | 04-26-2012 |
Sasha Bakhru, Providence, RI US
Patent application number | Description | Published |
---|---|---|
20140120162 | Bioadhesive Drug Delivery Compositions - Compositions containing one or more active agents, one or more bioadhesives elements, and one or more charge masking agents are described herein. In some embodiments, the one or more active agents are biomolecules or macromolecules, such as polysaccharides, proteins, peptides, or nucleic acids, which are charged at physiological pH. The one or more charge masking agents are selected based on the nature of the charge on the active agent. The compositions may also contain one or more controlled release materials, such as extended or sustained release materials or delayed release materials, in order to modify release of the active agent. | 05-01-2014 |
Sasha H. Bakhru, Providence, RI US
Patent application number | Description | Published |
---|---|---|
20130137702 | ANTICOAGULANT REVERSAL AGENTS - Novel anticoagulant reversal compounds are disclosed, as well as methods of making the compounds, pharmaceutical compositions including the compounds, methods of using the compounds to reverse the anticoagulant effects of coagulation inhibitors, and diagnostic assays comprising the compounds. | 05-30-2013 |
20140178479 | Concentrated Felbamate Formulations for Parenteral Administration - Formulations of a neuroprotective agent for parenteral administration are described herein. The formulation is in the form of a concentrated (supersaturated) solution or a concentrated suspension of microparticles. The suspension medium or the solution solvent carrier may also contain dissolved neuroprotective agent. For the supersaturated solutions, the agent is dissolved at high concentrations of at least about 1% by weight, 5% by weight, 10% by weight, 15% by weight, or 20% by weight in a solvent suitable for parenteral administration. For the concentrated suspension, the microparticles have an effective particle size from about 100 nm to about 5 microns, preferably from about 50 nm to about 3 microns, more preferably from about 10 nm to about 2 microns. The formulations described herein can be used to treat a variety of neurological diseases/disorders and/or neurological injury or trauma. | 06-26-2014 |
20140207105 | Methods for Effectively and Rapidly Desensitizing Allergic Patients - Methods and compositions for delivering antigens to the lymphatic system in doses that desensitize patients to future exposure to antigens have been developed. Rapid desensitization is achieved by introducing small quantities of antigen into the lymphatic system. In preferred embodiments, the compositions are administered to yield therapeutically effective levels of antigen within the lymph, where macrophages reside in the greatest concentration, by intradermal administration, using for example, microneedles or microparticles, oral administration, using for example, enteric coated capsules or tablets, or autologous transfusion. In some embodiments, the methods and compositions for delivering antigens orally achieve uptake by the Peyer's patches of the small intestines. | 07-24-2014 |
20140271931 | Anti-Acne Topical Films - Topical formulations containing one or more pharmaceutically acceptable bioadhesive film-forming agent, one or more anti-acne agent, and an aqueous solvent in the form of a solution or suspension are described herein. The formulation may further contain one or more excipients, including evaporation suppressants, humectants, or plasticizers. When the formulation is contacted with the skin of a patient, the solvent evaporates and forms a thin, transparent, and solid bioadhesive film. The bioadhesive film adheres to the skin surface for a prolonged period of time and the anti-acne agent is released into the skin over a prolonged period of time. Typically, the bioadhesive film adheres to the skin for at least 60 minutes following administration of the formulation, preferably for at least 8 hours following administration, more preferably up to 24 hours following administration. The prolonged retention of the anti-acne agent at the site increases the amount of uptake into the skin. | 09-18-2014 |
Sasha H. Bakhru, Danbury, CT US
Patent application number | Description | Published |
---|---|---|
20150065423 | RAPID ACTING INJECTABLE FORMULATIONS - A rapid acting injectable formulation is provided comprising a therapeutic peptide and a vasodilatory agent. The therapeutic peptide has a molecular weight of greater than about 500 Daltons, and the vasodilatory agent is present in an amount effective to increase the absorption of the therapeutic peptide. A method of increasing absorption of a therapeutic peptide by using such a formulation is also provided. | 03-05-2015 |
Sasha H. Bakhru, Ridgefield, CT US
Patent application number | Description | Published |
---|---|---|
20150133769 | LABELED COMPOUNDS AND METHODS OF IMAGING, DIAGNOSING CARTILAGE DISORDERS AND DISEASES, AND MONITORING CARTILAGE HEALTH USING LABELED AND UNLABELED COMPOUNDS - Novel labeled compounds and metabolites thereof are disclosed, as well as pharmaceutical compositions including the compounds, and methods of using the labeled and unlabeled compounds, and specifically, 2-Amino-5-guanidino-pentanoic acid (3-{4-[3-(2-amino-5-guanidino-pentanoylamino)-propyl]-piperazin-1-yl}-propyl)-amide and metabolites thereof, for imaging, detecting and assessing disorders and diseases, such as arthritis and, more specifically, osteoarthritis by tracking proteoglycan and glycosaminoglycan content of cartilage. Also, pharmaceutical compositions comprising labeled and/or unlabeled 1,4-Bis(3-aminopropyl)piperazine are disclosed and methods of using the same. | 05-14-2015 |
Sunil Bakhru, San Jose, CA US
Patent application number | Description | Published |
---|---|---|
20120327763 | PREVENTING UPPER LAYER RENEGOTIATIONS BY MAKING PPP AWARE OF LAYER ONE SWITCHOVERS - A method may include establishing a first Point-to-Point Protocol (PPP) session on an interface, receiving an indication of a layer one failure, omitting for a period of time, an indication that the first PPP session on the interface is down, based on the indication of the layer one failure, establishing a layer one switchover to another interface based on the indication of the layer one failure, and attempting during the period of time, to establish a second PPP session on the other interface. | 12-27-2012 |